Skip to main content

#152795

Anti-PDL2 (soluble form) [Z64P2D3*H4] mAb

Cat. #152795

Anti-PDL2 (soluble form) [Z64P2D3*H4] mAb

Cat. #: 152795

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Programmed Cell Death 1 Ligand 2 (PDL2-Soluble form)

Class: Monoclonal

Application: ELISA ; IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ayham Alnabulsi

Institute: Vertebrate Antibodies Limited

Tool Details
Target Details
Applications
Handling
Related Tools

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-PDL2 (soluble form) [Z64P2D3*H4] mAb
  • Alternate name: B7 dendritic cell molecule, B7-DC, B7DC, bA574F11.2, Btdc, Butyrophilin B7 DC, Butyrophilin B7-DC, Butyrophilin B7DC, CD 273, CD273, CD273 antigen, MGC142238, MGC14224, PD 1 ligand 2, PD L2, PD-1 ligand 2, PD-L2, PD1 ligand 2, PD1L2_HUMAN, PDCD 1 ligand 2, PDCD1 ligand 2
  • Research fields: Immunology
  • Clone: Z64P2D3*H4
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; WB
  • Description: Monoclonal antibody which can aid understanding of programmed death ligand 2, in the secreted form. Background and Research Application PDL2 is involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.). PDL2 is an immune checkpoint receptor ligand which plays a role in negative regulation of the adaptive immune response.PD-L2 is one of two known ligands for Programmed cell death protein 1 (PD-1). PD-1, is a key immune checkpoint. Currently several anti-PD-1 antibodies or blockers are in cancer clinical trials and showing promising outcomes. This antibody will allow scientists examine, for the first time, the clinical significance of PDL2-secreted form.
  • Immunogen: Ovalbumin-conjugated synthetic peptide KAVFFKRHN
  • Immunogen uniprot id: Q9BQ51
  • Isotype: IgG2b kappa
  • Myeloma used: P3X63Ag8.653
  • Recommended controls: IHC: formalin-fixed, paraffin-embedded multi tumour tissue microarray

Target Details

  • Target: Programmed Cell Death 1 Ligand 2 (PDL2-Soluble form)
  • Tissue cell line specificity: IHC: formalin-fixed, paraffin-embedded multi tumour tissue microarray
  • Target background: Monoclonal antibody which can aid understanding of programmed death ligand 2, in the secreted form. Background and Research Application PDL2 is involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.). PDL2 is an immune checkpoint receptor ligand which plays a role in negative regulation of the adaptive immune response.PD-L2 is one of two known ligands for Programmed cell death protein 1 (PD-1). PD-1, is a key immune checkpoint. Currently several anti-PD-1 antibodies or blockers are in cancer clinical trials and showing promising outcomes. This antibody will allow scientists examine, for the first time, the clinical significance of PDL2-secreted form.

Applications

  • Application: ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Dry ice

Related Tools

  • Related tools: Anti-PDL2 (soluble form), Recombinant [Z64P2D3*H4]

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.